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Quality of lifeAbstract Aim: The aim of the study was to assess patient preference for the fixed-dose com-
bination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in patients
with HER2-positive early breast cancer in PHranceSCa (NCT03674112).
Materials and methods: Patients who completed neoadjuvant P þ H þ chemotherapy þ
surgery were randomised 1:1 to three intravenous (IV) P þ H cycles followed by three cycles
of PH FDC SC or vice versa (crossover) and then chose subcutaneous (SC) injection or IV
infusion to continue up to 18 cycles (continuation). Assessments were via patient and health-
care professional (HCP) questionnaires.
Results: One hundred and sixty patients were randomised (cut-off: 24 February 2020); 136
(85.0%, 95% confidence interval: 78.5e90.2%) preferred SC; 22 (13.8%) preferred IV; 2
(1.3%) had no preference. The main reasons for SC preference were reduced clinic time
(n Z 119) and comfort during administration (n Z 73). One hundred and forty-one
patients (88.1%) were very satisfied/satisfied with SC injection versus 108 (67.5%) with IV infu-
sion; 86.9% chose PH FDC SC continuation. HCP perceptions of median patient treatment
room time ranged from 33.0e50.0 min with SC and 130.0e300.0 min with IV. Most adverse
events (AEs) were grade 1/2 (no 4/5s); serious AE rates were low. AE rates before and after
switching were similar (cycles 1e3 IV / cycles 4e6 SC: 77.5% / 72.5%; cycles 1e3 SC
/ cycles 4e6 IV: 77.5% / 63.8%).
Conclusion: Most patients strongly preferred PH FDC SC over P þ H IV. PH FDC SC was
generally well tolerated, with no new safety signals (even when switching), and offers a quicker
alternative to IV infusion.
ª 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Intravenous pertuzumab plus trastuzumab (P þ H IV)
with chemotherapy is standard of care for
HER2-positive breast cancer (BC) both in the curative
early BC (EBC) (as neoadjuvanteadjuvant and adju-
vant treatment for patients at high risk of recurrence)
and metastatic settings [1e4]. Despite their clinical
benefits, they are infused sequentially over a long
time, with observation, cannulation, line flushing and
waiting times that can total hours. This is burden-
some for patients (especially those working
throughout treatment and with collapsed veins) and
healthcare systems. Repeated invasive IV treatments
can be inconvenient and painful for patients [5,6] and
a burden on medical centres’ time and resources [7].
A fixed-dose combination of P and H for subcu-
taneous injection (PH FDC SC) is US Food and Drug
Administration (FDA)- and European Medicines
Agency (EMA)-approved for HER2-positive BC and
offers less invasive, faster administration than IV in-
fusions. It has w8 min loading and w5 min mainte-
nance administration times and short observation times
(minimum 30 and 15 min, respectively), giving patientsconvenience. Flexible care is an important consideration
[8]; the FDA notes that PH FDC SC can be adminis-
tered at home by a healthcare professional (HCP) [9].
PH FDC SC contains the same active ingredients as
P þ H IV and is non-inferior in terms of P and H serum
trough concentrations, with comparable pathological
complete response (pCR) rates and safety profiles
(FeDeriCa study) [10].
While FeDeriCa focused on pharmacokinetics and
clinical outcomes, the PHranceSCa study was designed
to assess patients’ preferences for PH FDC SC and
P þ H IV in HER2-positive EBC. We report the pri-
mary results.
2. Materials and methods
2.1. Study design
PHranceSCa (NCT03674112) is a randomised, open-
label, international, multicentre, crossover, phase II
study conducted at 39 sites in 16 countries. The design
is shown in Fig. 1. Loading doses (P IV 840 mg; H IV
8 mg/kg; PH FDC SC 1200 mg P/600 mg H in 15 mL)
were only required for patients who had 6 weeks
J. O’Shaughnessy et al. / European Journal of Cancer 152 (2021) 223e232 225since their last neoadjuvant dose of P þ H IV at study
entry or had 6 weeks since their last study treatment
during the study. Maintenance doses (P IV 420 mg; H
IV 6 mg/kg; PH FDC SC 600 mg P/600 mg H in
10 mL) were used for subsequent administrations or
dose delays <6 weeks.2.2. Patients
Eligible patients were 18 years old, had histologically
confirmed HER2-positive (locally confirmed immunohis-
tochemistry 3þ and/or in situ hybridisation-positive) in-
flammatory, locally advanced or EBC, had completed
neoadjuvant P, H and chemotherapy and had subsequently
undergone surgery for BC. The neoadjuvant chemotherapy
regimen and number of neoadjuvant P þ H cycles were at
the physician’s and patient’s discretion. Patients had an
Eastern Cooperative Oncology Group performance status
of 0e1 and left ventricular ejection fraction 55% (by
echocardiography or multiple-gated acquisition scan).IV  S
IVSC
Fig. 1. Loading doses were only required for patients who had 6 or m
entry or had 6 or more weeks since their last study treatment during
trations or dose delays less than 6 weeks. Dose modifications were not
delayed to assess or treat adverse events. Treatment was discontinued f
The study was conducted in accordance with Good Clinical Practic
reviewed and approved by the institutional review board or ethics com
consent. DXCX, day X cycle X; EBC, early breast cancer; ER, oe
healthcare professional; HR, hormone receptor; IV, intravenous; NAC
complete response; PgR, progesterone receptor; PH FDC SC, fixed-do
injection; PPQ, Patient Preference Questionnaire; q3w, every 3 weeks
taneous; TASQ, Therapy Administration Satisfaction Questionnaire.
Study design. a P IV loading dose if needed: 840 mg; maintenance: 420
kg IV q3w. b PH FDC SC loading dose if needed: P 1200 mg/H 600 m
European Organisation for Research and Treatment of Cancer Quality
of study treatment visits as well as at 18 months, 2 years and 3 years f
investigator-reported adverse events, grade 3 adverse events, serious a
ejection fraction events) with severity determined according to the Nati
Events version 4.0; incidence of premature withdrawal from study treatm
laboratory test results.Ineligibility criteria included previous systemic therapy
(including chemotherapy, immunotherapy, HER2-targeted
agents, endocrine therapy [selective oestrogen receptor
modulators, aromatase inhibitors] and anti-tumour vac-
cines) for treatment/prevention of BC, except neoadjuvant
P, H and chemotherapy for current BC, serious cardiac
illness/medical conditions and impaired/inadequate organ/
bone marrow function.2.3. Assessments
The primary objective was to evaluate patient preference
for PHFDCSC in themodified intention-to-treat (mITT)
population, assessed as the proportion of patients who
preferred PH FDC SC based on question 1 of the Patient
Preference Questionnaire (PPQ): “All things considered,
which method of administration did you prefer?”
The PPQ, Therapy Administration Satisfaction Ques-
tionnaire, HCP Questionnaire (HCPQ), health-related
qualityof life and safetyassessmentsaredescribed inFig. 1.C
ore weeks since their last neoadjuvant dose of P þ H IV at study
the study. Maintenance doses were used for subsequent adminis-
allowed for HER2-targeted therapies, but administration could be
or disease recurrence, unacceptable toxicity or patient withdrawal.
e guidelines and the Declaration of Helsinki. The protocol was
mittee at each study site. All patients provided written informed
strogen receptor; chemo, chemotherapy; H, trastuzumab; HCP,
T, neoadjuvant chemotherapy; P, pertuzumab; pCR, pathological
se combination of pertuzumab and trastuzumab for subcutaneous
; R, randomisation via a web-based response system; SC, subcu-
mg q3w. H IV loading dose if needed: 8 mg/kg; maintenance: 6 mg/
g in 15 mL; maintenance: P 600 mg/H 600 mg in 10 mL q3w. c Via
of Life Questionnaire C30, at baseline, cycle 3, cycle 6 and the end
rom randomisation. d Via the incidence, nature and severity of all
dverse events and cardiac adverse events (including left ventricular
onal Cancer Institute’s Common Terminology Criteria for Adverse
ent; targeted vital signs and physical findings and targeted clinical
 IV  SC  SC  IV
Fig. 2. Reasons for exclusion between screening and randomisation: Did not meet inclusion criteria (n Z 11), met exclusion criteria
(n Z 10), patient decision (n Z 1) and out of window (n Z 1). H, trastuzumab; IV, intravenous; P Z pertuzumab; PH FDC SC, fixed-
dose combination of pertuzumab and trastuzumab for subcutaneous injection.
Patient disposition. a One patient in arm A had not yet started continuation treatment. b Seven patients in arm A and nine in arm B
completed continuation treatment but had not yet started the follow-up period. Data cut-off: 24 February 2020.
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The primary analysis was scheduled for when all patients
had completed their last crossover treatment. The inten-
tion-to-treat (ITT) population includes all randomised
patients. The mITT population includes all patients who
received 1 dose of PH FDC SC and P þ H IV during
crossover and answered PPQ question 1.
The planned sample size (140) was based on an
assumed 70% PH FDC SC preference. To achieve a
distance of approximately 8% from the estimated
proportion to 95% confidence interval (CI) limits, 126
were needed to evaluate preference. The final sample size
was increased to w140 patients to allow for 10% not
providing an evaluable assessment.
Analyses were conducted using SAS, version 9.04
(SAS Institute, Inc., Cary, NC, USA).3. Results
3.1. Population
Patient dispositions are shown in Fig. 2. Demographics
and baseline characteristics were balanced (Table 1).
3.2. Patient-reported outcomes
One hundred and thirty-six of 160 patients (85.0%, 95%
CI: 78.5e90.2) preferred PH FDC SC over P þ H IV
(22/160 [13.8%]) (Table 2).Of those who preferred PH FDC SC, most (92.6%)
indicated a “very/fairly strong” preference; the most
common reasonswere “requires less time in the clinic” and
“feelsmorecomfortableduringadministration” (Table2).
Of those who preferred P þ H IV, 63.6% indicated a
“very/fairly strong” preference; the most common rea-
sons were “feels more comfortable during administra-
tion” and “lower level of injection site pain” (Table 2).
Most patients (88.1%) indicated they were “(very)
satisfied” with PH FDC SC (67.5% with P þ H IV); most
(71.3%) felt “not at all” restricted while receiving PH FDC
SC (34.4%with PþH IV); 60.6% felt they “gained a lot of
time” or “gained some time” with PHFDC SC (4.4%with
PþH IV) (Table A1).
Treatment had no impact on patienteHCP speaking
time (PHFDCSC:85.0%;PþHIV:79.4%);most patients
had more than enough time to talk to their HCP during
treatment (PH FDC SC: 90.0%; PþH IV: 82.5%).
One hundred and thirty-nine of 160 patients (86.9%)
chose to continue with PH FDC SC after completing
crossover (arm A: 71/80 [88.8%]; arm B: 68/80 [85.0%]).
Mean changes from baseline in global health status/
health-related quality of life scale scores were minimal
and comparable between arms throughout (Fig. A1).
3.3. HCPQs
Nine hundred and fifty-seven of 960 HCPQs (99.7%)
had 1 question answered in the drug preparation room
during crossover (Table A2). Median PH FDC SC
preparation time was 5.0 min at all cycles
J. O’Shaughnessy et al. / European Journal of Cancer 152 (2021) 223e232 227(15.0e20.0 min for P þ H IV). HCPs’ perceptions of
time indicated that for 140/160 patients (87.5%), HCPs
agreed that PH FDC SC was quickest from preparation
start to administration completion. Most HCPs
“(strongly) agreed” that there would be less drug
wastage because of PH FDC SC being ready to use and
that preparation procedures and associated time staff
committed would be reduced if all IV infusions were
switched to SC injections.
Nine hundred and fifty of 960 HCPQs (99.0%) had
1 question answered in the treatment room duringTable 1
Baseline patient demographic and tumour characteristics for the intention
Arm A





American Indian or Alaska Native 5 (6.3)
Asian 8 (10.0)






ECOG performance status, n (%)
0 70 (87.5)
1 10 (12.5)
Number of cycles of prior neoadjuvant P þ H IV, n (%)
<4 5 (6.3)
4 75 (93.8)
Prior neoadjuvant chemotherapy regimen (IxRS), n (%)
Anthracyclines plus taxanes 55 (68.8)
Carboplatin plus taxanes 22 (27.5)
Taxanes only 3 (3.8)
Pathological complete response to prior neoadjuvant treatment (IxRS), n
pCR 52 (65.0)
Residual disease 28 (35.0)
Hormone receptor status (IxRS), n (%)
ER-positive and/or PgR-positive 53 (66.3)
ER-negative and PgR-negative 27 (33.8)
Histological subtype, n (%)a
Invasive carcinoma of no special type 44 (55.0)
Invasive lobular carcinoma 8 (10.0)








No residual tumour 1 (1.3)
GX/unknown 10 (12.5)
Clinical stage at presentation, n (%)
Stage IIeIIIA 68 (85.0)
Stage IIIBeIIIC 12 (15.0)
All patients were women. ECOG, Eastern Cooperative Oncology Grou
interactive voice/web response system; P, pertuzumab; pCR, pathological co
combination of pertuzumab and trastuzumab for subcutaneous injection.
a Patients may have had >1 subtype; therefore, the same patient may hacrossover (Table A3). The median patient time was
33.0e50.0 min with PH FDC SC and 130.0e300.0 min
with P þ H IV. Of this, the median administration time
was 7.0e8.0 min with PH FDC SC and 60.0e150.0 min
with P þ H IV.
3.4. Treatment exposure
During crossover, all patients received 3 cycles of each
formulation. IV delays were reported for 9/160 patients
(5.6%); SCdelayswere reported for 10/160 patients (6.3%).-to-treat population.
Arm B All patients (N Z 160)
80) PH FDC SC / P þ H IV (n Z 80)
47.0 47.0
22e80 22e80
3 (3.8) 8 (5.0)
4 (5.0) 12 (7.5)
2 (2.5) 4 (2.5)
67 (83.8) 129 (80.6)
4 (5.0) 7 (4.4)
69.6 68.0
47.5e119.0 46.4e119.0
70 (87.5) 140 (87.5)
10 (12.5) 20 (12.5)
10 (12.5) 15 (9.4)
70 (87.5) 145 (90.6)
53 (66.3) 108 (67.5)
23 (28.8) 45 (28.1)
4 (5.0) 7 (4.4)
(%)
50 (62.5) 102 (63.8)
30 (37.5) 58 (36.3)
51 (63.8) 104 (65.0)
29 (36.3) 56 (35.0)
50 (62.5) 94 (58.8)
4 (5.0) 12 (7.5)
1 (1.3) 2 (1.3)
1 (1.3) 1 (0.6)
1 (1.3) 1 (0.6)
26 (32.5) 55 (34.4)
2 (2.5) 3 (1.9)
34 (42.5) 72 (45.0)
37 (46.3) 67 (41.9)
2 (2.5) 3 (1.9)
5 (6.3) 15 (9.4)
68 (85.0) 136 (85.0)
12 (15.0) 24 (15.0)
p; ER, oestrogen receptor; H, trastuzumab; IV, intravenous; IxRS,
mplete response; PgR, progesterone receptor; PH FDC SC, fixed-dose
ve been counted in different categories.
Table 2
Patient preference in the modified intention-to-treat population.
Arm A Arm B All patients (N Z 160)
P þ H IV / PH FDC SC
(n Z 80)
PH FDC SC / P þ H IV
(n Z 80)
Preferred method of administration, n (%)
Total number of respondents 80 80 160
SC 70 (87.5) 66 (82.5) 136 (85.0)
IV 10 (12.5) 12 (15.0) 22 (13.8)
No preference 0 2 (2.5) 2 (1.3)
How strong is this preferencedSC?, n (%)
Total number of respondents 70 66 136
Very strong 48 (68.6) 44 (66.7) 92 (67.6)
Fairly strong 17 (24.3) 17 (25.8) 34 (25.0)
Not very strong 5 (7.1) 5 (7.6) 10 (7.4)
Main reasons for the preferencedSC, n (%)a
Total number of responses 143 139 282
Feels less emotionally distressing 21 (14.7) 25 (18.0) 46 (16.3)
Requires less time in the clinic 60 (42.0) 59 (42.4) 119 (42.2)
Lower level of injection site pain 14 (9.8) 18 (12.9) 32 (11.3)
Feels more comfortable during administration 41 (28.7) 32 (23.0) 73 (25.9)
Other reason 7 (4.9) 5 (3.6) 12 (4.3)
How strong is this preferencedIV?, n (%)
Total number of respondents 10 12 22
Very strong 4 (40.0) 8 (66.7) 12 (54.5)
Fairly strong 1 (10.0) 1 (8.3) 2 (9.1)
Not very strong 5 (50.0) 3 (25.0) 8 (36.4)
Main reasons for the preferencedIV, n (%)a
Total number of responses 17 25 42
Feels less emotionally distressing 3 (17.6) 4 (16.0) 7 (16.7)
Requires less time in the clinic 1 (5.9) 1 (4.0) 2 (4.8)
Lower level of injection site pain 4 (23.5) 7 (28.0) 11 (26.2)
Feels more comfortable during administration 8 (47.1) 6 (24.0) 14 (33.3)
Other reason 1 (5.9) 7 (28.0) 8 (19.0)
Percentages are based on the total number of respondents/responses in the respective question and treatment sequence. H, trastuzumab; IV,
intravenous; P, pertuzumab; PH FDC SC, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection.
a Patients are counted in several categories.
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(median, 5 cycles initiated [range: 2e8]); 137 patients
received SC injections (median, 5 cycles initiated [range:
1e9]). IV delays were reported for 2/21 patients (9.5%); SC
delays were reported for 17/137 patients (12.4%). One pa-
tient originally chose and received one P þ H IV dose
during continuation and then chose PH FDC SC for the
remaining cycles. The median exposure to neoadjuvant
PþH IVwas 4 cycles (range: 2e8). At clinical cut-off, the
median exposure to adjuvant P þ H (IV and SC) was 11
cycles (range: 6e15).3.5. Safety by crossover versus continuation period
Most adverse events (AEs) were grade 1/2 (none 4/5);
there were low rates of serious AEs, and no new safety
signals were identified (Table 3). Seventy patients per
arm experienced AEs (87.5%). The only grade 3 event
reported in >1 patient was device-related infection (one
each during the IV and SC periods). The only seriousAEs reported in >1 patient were the aforementioned
device-related infections and decreased ejection fraction
(two patients; considered treatment related during
crossover; grade 2).
Two patients discontinued treatment because of AEs:
one because of the aforementioned ejection fraction
decrease with SC injection and one because of disease
relapse during continuation. This latter patient also
experienced multiple AEs (nausea, ataxia, headache)
related to this relapse that led to treatment withdrawal,
all of which were grade 1/2 and considered unrelated to
P þ H IV; the grade 1 events (nausea, ataxia, headache)
were ongoing at cut-off.
The most common AEs (in 5% of patients in any
period) of any grade overall were radiation skin injury,
injection site reaction, diarrhoea, fatigue, arthralgia, hot
flush, headache, myalgia, rash and bone pain.
Anaphylaxis and hypersensitivity reactions
(defined as per the Sponsor’s AE grouped terms) were
reported for 4/160 patients (2.5%). All occurred with
Table 3
Adverse event profile during the crossover and continuation periods and during switching between formulations (safety population; all patients
who received 1 dose of any study drug).














Total number of patients
1 AE, n (%)
113 (70.6) 120 (75.0) 13 (61.9) 70 (51.1) 144 (90.0)
Total number of AEs, n 308 339 41 213 901
Total number of patients with 1, n (%):
AE with fatal outcome 0 0 0 0 0
Related AE with fatal outcome 0 0 0 0 0
Grade 3e5 AE 6 (3.8) 4 (2.5) 2 (9.5) 4 (2.9) 13 (8.1)
Related grade 3e5 AE 1 (0.6) 1 (0.6) 0 0 2 (1.3)
Cardiac AE (including LVEF
events)
3 (1.9) 5 (3.1) 0 1 (0.7) 9 (5.6)
Serious AE 6 (3.8) 2 (1.3) 0 3 (2.2) 10 (6.3)
Suspected causal relationship to study medication
Yes 30 (18.8) 58 (36.3) 2 (9.5) 27 (19.7) 79 (49.4)
Unknown 1 (0.6) 1 (0.6) 0 1 (0.7) 3 (1.9)
Local infusion site reaction 1 (0.6) 0 0 0 1 (0.6)
Systemic infusion-related reaction 6 (3.8) 0 0 0 6 (3.8)
Local injection site reaction 0 36 (22.5) 0 10 (7.3) 42 (26.3)
Systemic injection-related reaction 0 3 (1.9) 0 2 (1.5) 4 (2.5)
Switching Arm A Arm B All patients
(N Z 160)
P + H IV / PH FDC SC PH FDC SC / P + H IV









P + H IV
(cycles 4e6)
(n Z 80)
Total number of patients
with  AE, n1 (%)
62 (77.5) 58 (72.5) 62 (77.5) 51 (63.8) 140 (87.5)
Total number of AEs, n 192 143 196 116 647
Five most common AEs
(in 5% of patients), n (%)
Radiation skin injury 17 (21.3) 7 (8.8) 10 (12.5) 10 (12.5) 43 (26.9)
Injection site reaction 0 12 (15.0) 24 (30.0) 0 36 (22.5)
Diarrhoea 12 (15.0) 7 (8.8) 6 (7.5) 4 (5.0) 25 (15.6)
Fatigue 5 (6.3) 4 (5.0) 5 (6.3) 4 (5.0) 15 (9.4)
Hot flush 6 (7.5) 4 (5.0) 5 (6.3) 0 15 (9.4)
Percentages are based on n/N in the column headings. Multiple occurrences of the same event in one individual were counted only once except
for ‘Total number of AEs’ row in which multiple occurrences of the same event were counted separately. Included are events with onset from
the first dose of any study treatment through 28 days after the last dose of study treatment. When an event start date was partially or fully
missing and it was unclear to which treatment period the event should have been assigned, the event was assigned to all relevant treatment
periods. AE, adverse event; ARR, administration-related reaction; H, trastuzumab; IV, intravenous; LVEF, left ventricular ejection fraction;
P, pertuzumab; PH FDC SC, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection.
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actions (no actual anaphylaxis reported) which were
also considered administration-related reactions
(ARRs; please see the following paragraph), were
grade 1/2 and resolved.
ARRs were defined as “anaphylactic reaction (wide),
anaphylaxis and hypersensitivity and infusion-related
reactions and hypersensitivity, occurring within 24 h of
the end of administration of HER2-targeted therapy,
whether considered related or unrelated to study treat-
ment by the investigator.” Onset timing of local injection
site reactions was split between during/immediately after
and within 24 h of treatment. Onset timing of the single
local infusion site reaction was within 24 h of treatment.Systemic injection-related reactions related to SC
administration were experienced by 3/160 patients (1.9%)
during crossover and by 2/137 patients (1.5%) during
continuation. Onset timing of systemic injection-related
reactions was within 24 h of treatment. Onset timing of
systemic infusion-related reactions was equally split be-
tween during/immediately after and within 24 h of
treatment.
Other ARRs reported included headache, muscle
spasms (both 2/160 patients [1.3%]), head discomfort,
hypertension and vomiting (1/160 patients each [0.6%]).
All ARRs were grade 1/2 and resolved/resolving. None
led to withdrawal/interruption of study treatment/were
considered serious.
J. O’Shaughnessy et al. / European Journal of Cancer 152 (2021) 223e232230Cardiac AEs included ejection fraction decreases
(7/160 patients [4.4%]), arrhythmia, tachycardia and (car-
diac ventricular) hypokinesia (1/160 patients each [0.6%]).
No heart failures were reported. The ejection fraction de-
creases were reported during crossover in 3/160 patients
(1.9%) during IV administration and 4/160 patients (2.5%)
during SC administration. All were considered study
treatment related.Mostwere grade 2 and resolved (onewas
grade 3; another had not resolved). Treatment was inter-
rupted for four patients (two each for PH FDC SC and
P þ H IV) and withdrawn for one (PH FDC SC).
The hypokinesia event was during IV crossover,
considered non-serious, related to H, grade 2, resolved and
led to treatment interruption. The arrhythmia and tachy-
cardia events were each during SC administration in the
crossover and continuation periods, respectively. Both
were considered non-serious, grade 1 and unrelated to PH
FDC SC. The arrhythmia had not resolved.
3.6. Safety of switching between formulations
AE rates before and after switching were similar (cycles
1e3 IV / cycles 4e6 SC: 78% / 73%; cycles 1e3 SC
/ cycles 4e6 IV: 78% / 64%) and did not reveal any
new/clinically relevant safety concerns compared with
the overall analysis (Table 3).
4. Discussion
The PHranceSCa primary analysis demonstrated that the
vast majority of patients strongly preferred PH FDC SC
over PþH IV; the main reasons being that patients spent
less time in the clinic and that they were more comfortable
during administration.
Results were consistent with patients’ treatment
continuation choices: most chose to continue with SC
injection after experiencing both methods and were
(very) satisfied with PH FDC SC. Preferences were also
clear despite PH FDC SC’s relatively high injection
volume and viscous formula, which may have concerned
patients and less experienced HCPs [11]. However,
providing that the person administering the injection has
been trained to give it slowly, then patients, as reported
here, should not have undue pain.
Results were consistent with similar studies (PrefHer
[H SC versus H IV] [12,13] and PrefMab [SC versus IV
rituximab] [14]).
HCPQ data also supported PPQ data. There were
notable time savings for SC injection over IV infusion.
HCPs indicated that SC injection led to time savings for
preparation and administration and reduced the overall
time that patients spent in the treatment room and
resource use. PrefHer showed that H SC injectionreduces administration burden and chair time and that it
potentially optimises medical resource use [7].
There were no major changes during crossover in
patients’ health-related quality of life.
PH FDC SC was generally well tolerated. Incidences of
AEs during crossover were identical between treatment
arms,which indicates that treatment sequencehadnoeffect
on safety. Incidence during continuation was higher for IV
versus SC; however, results should be interpreted with
caution, as only 21 patients were evaluable for safety with
IV infusion. There was a higher proportion of treatment-
related AEs with PH FDC SC during crossover and
continuation, the most common events being injection site
reactions, as expected. This was also true for ARRs.
Switchingbetween IVandSCadministration,orviceversa,
was also well tolerated. Overall, safety results are support-
ive of those seen in FeDeriCa [10].
Our results provide important information not only
for clinicians but also for patients. PH FDC SC use
means that patients gain time for daily activities even
with hospital visits every 3 weeks and that central
venous access devices can be removed sooner, reducing
the risk of morbidity. Another advantage is that pa-
tients do not need to go to an infusion room, neces-
sarilydtreatment can be administered by trained
nurses outside of the hospital setting. There may be an
added benefit that patients may feel more comfortable
away from treatment rooms. In PrefHer, 60.4% of
patients would hypothetically have preferred SC home
administration [13]. This concept of flexible care is
being investigated in an ‘oncology hospital-at-home
program’ in the US, which reported fewer hospital-
isations and emergency department visits and reduced
costs versus standard processes [15]. Chemotherapy at
home is a well-embedded UK practice. A UK study
demonstrated that home care for patients with cancer,
patients with chronic conditions and those needing
end-of-life care may benefit patients with regard to
better adherence, reenablement, for example, resuming
or continuing daily activities, improved quality of life,
improved patient activation and financial savings [16].
The opportunity to move PH FDC SC administration
by an HCP to the home was acknowledged by the
FDA [9] and is particularly pertinent during the
COVID-19 pandemic as a means of reducing the risk
of infection associated with visiting hospitals (and the
subsequent potential complications of COVID-19
infection in patients with cancer) [8]. An expanded
access study (NCT04395508) is evaluating the safety of
home-administered PH FDC SC by home health
nurses. In addition to preparation and administration
time savings, PH FDC SC has a reduced observation
time and may assist with avoiding having too many
J. O’Shaughnessy et al. / European Journal of Cancer 152 (2021) 223e232 231patients together in the hospital at the same time. The
clear preference expressed by most patients highlights
the importance of HCPepatient dialogue, which was
not impacted by PH FDC SC.
Limitations include the small number of patients in
the IV continuation period and the lack of mature effi-
cacy data. pCR data are available in FeDeriCa [10].5. Conclusions
PHranceSCa showed that most patients strongly
preferred PH FDC SC over P þ H IV. PH FDC SC
was generally well tolerated, with no new safety signals
(even when switching from P þ H IV to PH FDC SC
or vice versa) and offers a quicker alternative to IV
infusion.Data sharing
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